在肝细胞癌中通过ferroptotic机制破译索拉芬尼抗性
Linlin Che1, Liujing Zhu1, Ling Zhou2
1Department of Immunology and Pathogenic Biology, School of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, PR China.
在先进的HCC中,可通过向铁死来克服sorafenib耐药性. 像Nrf2 / SLC7A11 / GPX4和脂质代谢这样的关键途径对于逆转肝癌中索拉芬尼布耐药性至关重要.
科学领域:
- 肝细胞癌 (HCC) 研究研究
- 细胞死亡机制 细胞死亡机制
- 在瘤学中的耐药性.
背景情况:
- 索拉费尼布是高级HCC的标准治疗方法,但耐药性限制了它的有效性.
- 铁,一种依赖于铁的细胞死亡,是克服索拉芬尼布耐药性的潜在策略.
- 了解铁亡的分子调节剂是改善HCC治疗结果的关键.
研究的目的:
- 系统地审查 sorafenib 耐药 HCC 中铁灭的调节轴.
- 探索铁亡途径和脂质代谢之间的交叉关系.
- 确定针对铁亡的新兴治疗策略.
主要方法:
- 在ferroptosis中关键调节轴的文献综述.
- 对Nrf2/SLC7A11/GPX4抗氧化轴的分析.
- 检查脂质代谢和诱导铁亡的轴 (ACSL4/LPCAT3).
主要成果:
- Nrf2,SLC7A11和GPX4形成一个抗氧化剂轴,抑制铁亡.
- 脂质新陈代谢重塑促进HCC中的铁性耐药性.
- 多个分子轴,包括FSP1-CoQ10和P53/ATF4,调节铁亡.
结论:
- 向铁亡途径提供了一种有希望的方法,以使先进的HCC对sorafenib重新敏感.
- 了解抗氧化剂和脂质代谢途径的相互作用对于组合疗法至关重要.
- 药理学或放射治疗对这些铁灭调节者的向可能会改善患者的治疗结果.
更多相关视频
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
09:32Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
Published on: October 17, 2025
相关概念视频
Treatment Resistant Cancers
Necrosis
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Targeted Cancer Therapies
There are several types of targeted therapies against...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
